The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The biosimilar market in Europe was valued at US$ 6,735 Million in 2021.
We expect the biosimilar market in Europe to exhibit a CAGR of 22.8% during 2022-2027.
The rapid patent expiration of various blockbuster biologics, coupled with the increasing awareness
pertaining to the efficiency and safety of biosimilars, is currently driving the biosimilar market in
The sudden outbreak of the COVID-19 pandemic had led to the delayed clinical trials for biosimilars
due to the rising focus on the production of effective vaccines against coronavirus infection, thereby
negatively impacting the biosimilar market in Europe.
Based on the molecule, the biosimilar market in Europe can be bifurcated into infliximab, insulin
glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab, follitropin alfa, and
adalimumab. Currently, infliximab holds the majority of the total market share.
Based on the indication, the biosimilar market in Europe has been divided into auto-immune
diseases, blood disorder, diabetes, oncology, growth deficiency, and female infertility. Among these,
auto-immune diseases currently exhibit a clear dominance in the market.
Based on the manufacturing type, the biosimilar market in Europe can be segmented into in-house
manufacturing and contract manufacturing. Currently, in-house manufacturing represents the
On a regional level, the market has been classified into Italy, Germany, United Kingdom, France,
Spain, and rest of Europe, where Italy dominates the biosimilar market in Europe.
Some of the major players in the biosimilar market in Europe include Novartis, Pfizer, Teva, Celltrion,
Samsung Bioepis, Amgen, Apotex ,Ratiopharm, Mylan, Merck Sharp & Dohme, Eli Lilly, Accord
Healthcare Ltd, Boehringer Ingelheim, Hexal Ag, Stada Arzneimittel Ag, etc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at